CELLUMED Co Ltd
049180
Company Profile
Business description
CELLUMED Co Ltd is a Korean company which is engaged in manufacturing and sale of medical equipment and biosimilars. Its products portfolio includes allografts for tissue repair, bone sponges, bone powders and demineralized bone matrixes (DBMs) for bone regeneration and biosimilars such as bone morphogenetic protein 2 (BMP2) reagents and others. It also produces medical devices, such as spinal fixation systems, joint replacements, and navigation systems.
Contact
Acetechno Tower 9 402
Gasan-dong
Geumcheon-gu
Seoul153-782
KORT: +82 221040475
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2025
Employees
91
Stocks News & Analysis
stocks
Short-term pain for long-term gain for undervalued ASX share
Cost reductions lower our profit estimates but should lead to improved long-term outcomes.
stocks
Qantas earnings: Jetstar capitalising on weaker domestic competition
Qantas’ budget brand performing well, with segment earnings up 55%.
stocks
Nvidia Earnings: No signs of a slowdown in demand for AI chips
A selloff in Nvidia stock on the earnings news looks like a buying opportunity to us.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,066.80 | 60.40 | -0.66% |
| CAC 40 | 7,654.25 | 53.65 | -0.70% |
| DAX 40 | 23,487.33 | 550.00 | -2.29% |
| Dow JONES (US) | 45,295.81 | 249.07 | -0.55% |
| FTSE 100 | 9,116.69 | 79.65 | -0.87% |
| HKSE | 25,532.24 | 35.69 | 0.14% |
| NASDAQ | 21,279.63 | 175.92 | -0.82% |
| Nikkei 225 | 42,186.59 | 123.90 | -0.29% |
| NZX 50 Index | 13,082.26 | 50.90 | -0.39% |
| S&P 500 | 6,415.54 | 44.72 | -0.69% |
| S&P/ASX 200 | 8,795.40 | 63.60 | -0.72% |
| SSE Composite Index | 3,850.38 | 7.75 | -0.20% |